IVD rapid testPOCT channel

Shanghai Yijun Medical Technology — YIJUN H-FABP rapid test kit

Urine-based H-FABP rapid test kit для in-vitro qualitative detection of heart-type fatty acid-binding protein в human urine, поддерживающий auxiliary diagnosis of acute myocardial infarction в medical institutions.

IVD product showcase + acute myocardial infarction auxiliary testing page + medical channel cooperation inquiry page.

Shanghai Yijun Medical Technology Co., Ltd. YIJUN H-FABP rapid test kit poster for medical diagnostics
Shanghai Yijun Medical Technology Co., Ltd. H-FABP rapid test rollup banner and product highlightsShanghai Yijun Medical Technology Co., Ltd. H-FABP test kit instruction and product package

Product Overview

YIJUN H-FABP Rapid Test Kit — это in-vitro diagnostic reagent kit для detection of heart-type fatty acid-binding protein в human urine.

Согласно promotional materials, H-FABP быстро высвобождается после myocardial injury и может быть обнаружен в urine. Продукт позиционируется как non-invasive, convenient и rapid auxiliary testing tool для medical institutions.

Shanghai Yijun Medical Technology Co., Ltd. H-FABP rapid test kit product overview and use instruction

Key Product Advantages

Urine-based testing
Non-invasive sampling
Rapid response
Simple operation
Clinical auxiliary reference
Early indication support
Sensitive monitoring
Suitable for medical institutions
Designed for H-FABP qualitative detection
Supports acute myocardial infarction auxiliary diagnosis

H-FABP Marker Explanation

H-FABP означает heart-type fatty acid-binding protein. В brochure он описывается как белок, богатый в myocardial tissue, и как potential early marker для myocardial injury.

Brochure объясняет, что H-FABP имеет small molecular size и может быть обнаружен примерно в течение 3 часов после myocardial injury, что делает его reference marker для early myocardial injury evaluation.

Shanghai Yijun Medical Technology Co., Ltd. H-FABP marker explanation and clinical reference material

Market & Clinical Need

В brochure указано, что deaths from acute myocardial infarction in China превышают 1.3 million cases per year, with an annual growth rate of 7.8%. Также подчеркивается, что early diagnosis still has unmet clinical needs.

Материал подчеркивает, что time is life for AMI, and early rapid detection can help support clinical decision-making.

Testing Method

Method 1: drop urine sample into the sample well and read the result after standing for 5-15 minutes.
Method 2: collect urine with a disposable urine cup, insert the test strip into the urine sample, and read the result after 5-15 minutes.
Result interpretation includes positive, negative and invalid result examples.
Shanghai Yijun Medical Technology Co., Ltd. urine H-FABP rapid test method and result interpretation

Registration & Compliance Information

Promotional materials показывают Chinese medical device registration information и product registration certificate content.

The page presents the product as an IVD test kit for medical institutions and avoids exaggerated claims. Market access, registration, import approval and clinical application requirements may vary by country or region.

Shanghai Yijun Medical Technology Co., Ltd. Chinese medical device registration and product certificate material

Продукты и технические страницы

Application Scenarios

Hospitals
Emergency departments
Clinics
Medical laboratories
Physical examination centers
Primary healthcare institutions
POCT testing scenarios
Medical device distributors
IVD product channels
Acute myocardial infarction auxiliary testing
Myocardial injury marker monitoring

Cooperation Models

Medical device distribution
IVD reagent channel cooperation
Hospital and clinic supply
POCT product cooperation
Regional agency cooperation
OEM / ODM discussion
Public health project supply
Medical laboratory cooperation
Import registration cooperation
Product catalog cooperation
Training and after-sales support

Compliance Notice

The information on this page is for business introduction, product distribution discussion and market cooperation only. This product is an in-vitro diagnostic product for medical institution use. It should not be used as the sole basis for diagnosis or treatment decisions. Clinical interpretation should be combined with symptoms, ECG and other laboratory indicators. Product registration, import approval, advertising claims and clinical application requirements may vary by country or region. Partners should verify local regulations before distribution or promotion.